ATRA : Insider Transactions for Atara Biotherapeutics, Inc.

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

New Search

Get Insiders for :

Atara Biotherapeutics, Inc. (ATRA)

$0.61

0.01 (1.06%) as of 4:30 Fri 5/17

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

108,674,000

Market Cap:

66.29(M)

Last Volume:

Avg Vol:

52 Week Range:

$0.2298 - $2.31

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 707

Guru Rank Value : 1.9

Guru Occurances : 1


6 Months 1 Year 2 Year

Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	816,825	816,825
Total Buy Value	$0	$0	$194,885	$194,885
Total People Bought	0	0	3	3
Total Buy Transactions	0	0	4	4
Total Shares Sold	56,192	56,192	208,638	386,254
Total Sell Value	$40,460	$40,460	$210,247	$883,580
Total People Sold	5	5	6	9
Total Sell Transactions	5	5	18	37
End Date	2024-02-18	2023-11-17	2023-05-19	2022-05-19

Adjust Filter Settings

Records found: 731

Page 17 of 30

Filer's Name

Relation Title

Off-Dir-10%

Tran. Date

Form

Action

Price

Mkt Value

D/I

Shares

Holdings

Rank

3m +/-

Form

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-12-28

$15.15

$33,330

I/I

(2,200)

408,778

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-12-13

$14.73

$32,406

I/I

(2,200)

410,978

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-12-12

$14.56

$32,032

I/I

(2,200)

413,178

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-11-30

$14.40

$31,680

I/I

(2,200)

415,378

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-11-29

$14.09

$30,998

I/I

(2,200)

417,578

Soffer Gad

EVP & Chief Strategy Officer

• – –

2017-11-17

$15.00

$105,000

D/D

(7,000)

256,236

Clark Mitchall G.

EVP & Chief R & QA Officer

• – –

2017-11-16

$14.20

$46,718

D/D

(3,290)

163,052

Gallagher Carol Giltner

Director

– • –

2017-11-16

$14.20

$16,813

D/D

(1,184)

109,738

Fust Matthew K

Director

– • –

2017-11-15

$0.00

D/D

1,602

30,503

Clark Mitchall G.

EVP & Chief R & QA Officer

• – –

2017-11-15

$0.00

D/D

7,212

166,342

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-11-15

$0.00

D/D

5,908

743,675

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-11-15

$13.36

$21,429

D/D

(1,604)

342,530

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-11-15

$0.00

D/D

829

344,134

Mcgrath John

EVP & Chief Financial Officer

• – –

2017-11-15

$0.00

D/D

7,697

128,654

Gallagher Carol Giltner

Director

– • –

2017-11-15

$0.00

D/D

2,366

110,922

Soffer Gad

EVP & Chief Strategy Officer

• – –

2017-11-15

$0.00

D/D

4,146

263,236

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-11-14

$13.41

$29,502

I/I

(2,200)

419,778

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-11-13

$13.53

$29,766

I/I

(2,200)

421,978

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-10-27

$13.60

$29,920

I/I

(2,200)

424,178

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-10-26

$13.57

$29,854

I/I

(2,200)

426,378

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-10-16

$14.35

$86,100

D/D

(6,000)

343,305

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-10-12

$14.78

$32,516

I/I

(2,200)

428,578

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-10-11

$15.25

$33,550

I/I

(2,200)

430,778

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-09-20

$15.56

$34,232

I/I

(2,200)

432,978

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-09-19

$15.51

$34,122

I/I

(2,200)

435,178

731 Records found	Previous 10 11 12 13 14 15 16 17 18 19 Next	Page 17 of 30

Transaction Code Key:				Ownership Code Key
B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
OE	- Options Exercised	A	- Acquired
IO	- Initital Ownership	D	- Disposed

Summary:

Chart:

3m +/-: